Asimov

Overview

Asimov is a synthetic biology company offering contract cell line development (CLD) and upstream process development services for therapeutic biologics, cell therapies, and gene therapies. The company combines proprietary genetic engineering tools, cloud-based design software (Kernel), and GMP-grade host cell lines to enable clients to develop high-performance producer cell lines.

Core Service Offerings

Cell Line Development (CHO Edge System)

• Develops stable CHO-based cell lines for monoclonal antibodies and other biologics
• Typical titers of 8–11 g/L or higher across modalities
• Guarantees minimum 5 g/L for mAb IgG; if below threshold, CLD campaign and commercial-use rights are free
• Timeline: ~4 months from sequence to research cell bank delivery
• Includes in-house analytical development for product characterization
• Monoclonality verification via Cytena F-sight and Solentim Cell Metric imaging
• Fed-batch scale-up using Ambr 15 and Ambr 250 bioreactors
• Delivers clonal cell banks with CMC-compliant documentation and platform process for tech transfer

Lentiviral Vector Production (LV Edge System)

• Off-the-shelf LV Edge Packaging cell line achieving titers exceeding traditional transient transfection
• Single-plasmid transfection system (vs. standard four-plasmid process)
• Reduces GMP plasmid cost, process complexity, and supply chain risk
• Licensed to AGC Biologics' Cell and Gene Center of Excellence in Milan for commercial manufacturing
• Engineered HEK293 cell line with inducible viral genes and supporting software

AAV Vector Production (AAV Edge System)

• End-to-end payload design and gene therapy production tools
• Achieves titers up to 6E15 vg/L

RNA Therapeutics (RNA Edge System)

• Sequence design through wet lab validation in weeks
• Delivers high-confidence candidates

Technology Platform

Kernel Software: Cloud-based design and optimization tool for genetic constructs, codon optimization, vector design, and biophysical simulation across different cell types.

Genetic Parts Library: Over 1,000 experimentally validated genetic parts including transposases, expression vectors, inducible systems, and tissue-specific promoters.

Host Cell Lines: Engineered, GMP-banked host cells with regulatory documentation for therapeutic applications.

Proprietary Transposase: Drives >80% titer stability over 75 generations in stable clones.

Engagement Models

Asimov offers flexible collaboration options:

• Full service: Client provides sequence; Asimov performs CLD and process development in-house, delivering clonal cell banks and tech-transfer documentation
• Hybrid: Client uses Asimov software and host cells to perform in-house CLD with technical support
• Tools only: Client receives software access, DNA constructs, and GMP host cells for independent development

Regulatory & Quality

• CMC-compliant documentation provided with cell banks
• Platform processes designed for regulatory filing
• Team comprises scientists with combined decades of experience developing clinical-grade cell lines
• Collaborations with established CDMOs (e.g., AGC Biologics) for manufacturing scale-up

Research & Development

• DARPA ASKE (Automating Scientific Knowledge Extraction) contract awardee for developing physics-based AI design engine for biology
• Focus on multi-omics cellular measurements, structured biological metadata, and hybrid AI architectures (deep learning, reinforcement learning, mechanistic modeling)